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Abstract
Background:  Despite surveillance efforts, unexpected and serious adverse drug reactions (ADRs)
repeatedly occur after marketing. The aim of this article is to analyse ADRs reported by available ADR
signal detection approaches and to explore which information about new and unexpected ADRs these
approaches have detected.
Methods: We selected three therapeutic cases for the review: antibiotics for systemic use, non-steroidal
anti-inflammatory medicines (NSAID) and selective serotonin re-uptake inhibitors (SSRI). These groups
are widely used and represent different therapeutic classes of medicines. The ADR studies were identified
through literature search in Medline and Embase. The search was conducted in July 2007. For each
therapeutic case, we analysed the time of publication, the strengths of the evidence of safety in the different
approaches, reported ADRs and whether the studies have produced new information about ADRs
compared to the information available at the time of marketing.
Results: 79 studies were eligible for inclusion in the analysis: 23 antibiotics studies, 35 NSAID studies, 20
SSRI studies. Studies were mainly published from the end of the 1990s and onwards. Although the drugs
were launched in different decades, both analytical and observational approaches to ADR studies were
similar for all three therapeutic cases: antibiotics, NSAIDs and SSRIs. The studies primarily dealt with
analyses of ADRs of the type A and B and to a lesser extent C and D, cf. Rawlins' classification system. The
therapeutic cases provided similar results with regard to detecting information about new ADRs despite
different time periods and organs attacked. Approaches ranging higher in the evidence hierarchy provided
information about risks of already known or expected ADRs, while information about new and previously
unknown ADRs was only detected by case reports, the lowest ranking approach in the evidence hierarchy.
Conclusion: Although the medicines were launched in different decades, approaches to the ADR studies
were similar for all three therapeutic cases: antibiotics, NSAIDs and SSRIs. Both descriptive and analytical
designs were applied. Despite the fact that analytical studies rank higher in the evidence hierarchy, only
the lower ranking descriptive case reports/spontaneous reports provided information about new and
previously undetected ADRs. This review underscores the importance of systems for spontaneous
reporting of ADRs. Therefore, spontaneous reporting should be encouraged further and the information
in ADR databases should continuously be subjected to systematic analysis.
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Background
The thalidomide catastrophe around 1960 and additional
experiences such as serious adverse drug reactions to high
oestrogen oral contraceptives in the 1960s were probably
the main reasons for the increasingly stringent require-
ments set to document development safety and the estab-
lishment of spontaneous reporting systems [1,2]. Over the
years, the repeated occurrence of unexpected, serious
adverse drug reactions (ADRs) has attracted wide profes-
sional and public attention, with the result that doubt has
been cast on the effectiveness and quality of drug safety
surveillance systems. The COX-2 scandal resulting in
worldwide withdrawal of Vioxx®  (rofecoxib) from the
market in 2004 is a recent example of an ADR case that
emerged unexpectedly and took the world by surprise [3].
Several other ADR cases have been discovered after mar-
keting; well known are fenfluramine and the risk of pul-
monal hypertension, vigabatrine and visual field defects
and tolcapone and the risk of liver toxicity [4-6]. The
repeated occurrence of serious ADR cases after medicines
have been released on the market questions the extent to
which existing systems and methods for predicting ADRs
are effective [7]. Information about the ADR profile of a
new medicine appears from observations made during the
clinical development process [8,9]. The gold standard for
the design of these clinical trials is the randomised con-
trolled clinical trial (RCCT) [8,9]. The RCCT was designed
to measure efficacy rather than ADRs as outcome. The
design of the RCCT as hypothesis testing in itself sets nar-
row limits for the detection of information about serious
and unexpected ADRs due to the short treatment period,
the relatively small number of carefully selected partici-
pants in the trial, fixed drug doses, and hospital settings
that do not reflect the conditions under which the medi-
cines are used after marketing [8,9]. Data on well-recog-
nised, easily detectable ADRs may potentially be observed
in RCCTs, but unknown, rare or long-term adverse effects
are seldom detected in these trials due to the limitations
of the RCCT. Detection of unknown or rare ADRs may
include other pharmacovigilance designs, e.g. the sponta-
neous reporting systems, cohort or case-control studies
[1,10-12]. This article aims to review ADRs reported by
available ADR signal detection approaches and to explore
which information about new and unexpected ADRs
these approaches have detected.
Methods
We selected three different therapeutic groups of medi-
cines for review. The groups were characterised by differ-
ent:
a. Therapeutic groups
￿ Antibiotics for systemic use
￿ Non-steroidal anti-inflammatory drugs (NSAIDs)
￿ Selective serotonin re-uptake inhibitors (SSRIs)
b. Market launch
Antibiotics were first marketed in the 1940s and NSAIDs
in the 1960s, while SSRIs were not launched until the
middle of the 1980s (internal documents, The Danish
Medicines Agency).
c. ADR profiles
The therapeutic categories present different ADR profiles
due to their specific pharmacological characteristics and
functions.
Literature search
Studies were identified through Medline (from 1966) and
Embase (from 1989) using the following MESH terms:
serotonin re-uptake inhibitors, anti-inflammatory agents,
non-steroidal, anti-bacterial agents, adverse drug reaction
reporting systems, pharmacoepidemiology and the key
words: adverse drug reactions and information in combi-
nation. The literature search was conducted in July 2007
without language restriction. Studies written in non-Euro-
pean languages were later excluded. To be considered rel-
evant for this review, articles had to be empirical in origin
and focus on signal detection. Titles and abstracts of the
search results were screened and relevant articles identi-
fied. The reference lists of included publications were
hand-searched for possible additional relevant studies.
Non peer-reviewed articles or unpublished observations
were not considered. A flow chart of the study selection
process for the therapeutic cases is illustrated in figure 1.
Characteristics of the included studies
We developed a taxonomy inspired by general guidelines
for pharmacoepidemiological research to analyse the
studies systematically [13]. The taxonomy covers the fol-
lowing characteristics: publication year, design, method,
explored medicine and adverse drug reactions, geographic
setting, sampling period, sample size, outcome measures
and results. We extracted and compared the results of pub-
lished empirical studies in which various signal detection
methods were used. Extracted information was entered
into data sheets, one for each article. Data were extracted
and handled by the first author and checked by the second
author.
Analyses
For each of the three selected therapeutic groups, we ana-
lysed the time of publication, the strengths of the evidence
in the different approaches, reported ADRs and whether
the studies had produced new information about ADRsBMC Clinical Pharmacology 2009, 9:4 http://www.biomedcentral.com/1472-6904/9/4
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compared to the information available at the time of mar-
keting.
Classification of the tested/detected ADRs
For each included literature reference, the ADRs tested or
detected via the various signal detection approaches were
classified according to Rawlins' classification system [14].
An overview of the classification system is shown in table
1. The reported/detected ADRs were also classified accord-
ing to System Organ Classes in keeping with MedDRA ter-
minology [13].
Classification of applied approaches
The explored approaches were classified into analytical or
observational approaches according to Strom's defini-
tions [13]. Case-control and cohort studies are classified
as analytical methods, while spontaneous reporting, case
series/case reports and PEM studies are observational
[13].
Time of publication
For each therapeutic group, we analysed whether there
was a connection between time of publication and the
applied study design.
Strength of evidence
Evidence-based medicine operates with an evidence hier-
archy for evaluating the quality of the various study
designs used for therapeutic studies [13]. At the top of this
hierarchy are the meta-analyses (level 1), followed by
RCCTs at the second level and other controlled trials at the
third level. Cohort studies are placed at the fourth level,
followed by case-control studies at the fifth level. At the
Flow chart of the study selection process for the cases Figure 1
Flow chart of the study selection process for the cases.
Potentially relevant references identified from literature 
searches (n = 327) 
Studies with signal detection of ADRs as objective 
(n= 148) 
Included studies (n =79)  
Excluded studies:  
Non peer-reviewed articles (n = 9) 
Consumption studies (N = 6) 
Surveys (N = 5) 
Studies not focusing on signal 
detection (N = 40) 
Articles not available (N = 1)
Excluded studies:  
Therapeutic drug monitoring studies 
of hospitalised patients (n = 27) 
No signal detection (n = 150) 
Interim analysis (n= 3) 
Titles in non-European languages (6) BMC Clinical Pharmacology 2009, 9:4 http://www.biomedcentral.com/1472-6904/9/4
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bottom of the evidence hierarchy are cross-sectional sur-
veys (level 6) and anecdotal case reports (level 7) [13].
Results
The literature search identified 327 potentially relevant
references for all three therapeutic groups, 149 of which
were selected from the titles and abstracts and further
screened for relevance. Eventually 79 references were
included in this analysis. A flow chart of the selection and
exclusion process is illustrated in figure 1. The included
studies were distributed on the three therapeutic cases as
follows: antibiotics: 23 studies; NSAID: 35 studies; SSRI:
20 studies. One reference was not accessible.
ADR detection approaches applied
Table 2 provides an overview of the categorisation of the
designs used in the included studies and their rank in the
evidence hierarchy [13]. As the table indicates, the major-
ity of the included studies dealt with analyses of data
reported in Prescription Event Monitoring (PEM) pro-
grams and ADRs reported to national ADR databases,
approaches ranking at levels six and seven in the evidence
hierarchy.
Study characteristics
Tables 3, 4 and 5 display the characteristics and descrip-
tions of the analysed studies for each therapeutic case [15-
Table 1: Rawlins' classification system of ADRs
Type Definition
A Dose-dependent ADRs related to the pharmacological effect of the drug:
• Increased pharmacological effect
￿ ADRs that occur secondarily to the desired pharmacological effect
￿ ADRs due to other well known pharmacological effects
B Sensitivity reactions – not dose-dependent
￿ Allergic reactions
￿ Idiosyncratic reaction
C Long-term ADRs
￿ Carcinogines
￿ Teratogenes
￿ Chronic organ damage
D Drug-drug interactions
￿ Pharmacodynamic
￿ Pharmacokinetic
￿ Non-classifiable
Table 2: The analysed studies categorised by study design
Study design Rank in evidence hierarchy Therapeutic
cases
Antibiotics NSAIDs SSRIs Total
Cohort 4 5 4 1 10
Case control 5 2 3 2 8
PEM* 6 2 9 4 15
National ADR databases 7 7 14 11 32
Case series 7 2 3 1 6
Case reports 7 5 2 1 8
Total number of studies 23 36 20 79
*Prescription Event Monitoring StudiesBMC Clinical Pharmacology 2009, 9:4 http://www.biomedcentral.com/1472-6904/9/4
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Table 3: Characteristics of studies of the occurrence of ADRs related to antibiotics use
Reference Setting Medicines ADRs Sampling 
period
Sample size Outcome
measures
Results
(95% CI)
Type of 
ADRs
Case control studies
Czeizel 1999 [15] HU Erythromycin Teratology 1980–1996 113 cases/38,151 
controls
OR 1.1; 0.5–2.3 C
Seeger 2006 [16] Fluoroquinolones Achilles tendon 
rupture
1997–2001 947 cases/
18,940 controls
OR 1.2; 0.9–1.7 B
Cohort studies
Chysky 1991[17] DE Ciprofloxacin Not specified 44 days 634 patients % ADRs Different 
categories 
reported
A/B
Derby 1993 [18] AU Flucloxacillin Cholestatic 
hepatitis
45 days 132,087 patients PRR/100,000 users 7.6; 3.5–13.9 B
Jick 1994 [19] AU Flucloxacillin Cholestatic 
hepatitis
1991–1992 77,552 patients PRR/
100,000 users
6.5; 2.7–15.1 B
Derby 1993b [20] AU Erythromycin Cholestatic 
hepatitis
- 366,064 patients PRR/100,000 users 3,6; 1.9–6.1 B
Heymann 2007 [21] Israel Penicillins Pemphigus 1997–2001 150,000 patients OR 2.03; 1.56–2.64 B
PEM
Clark 2001 [22] UK Fluoroquinolones Cardiovascular 
events
1988–1991 36,410 patients CRR 
(crude relative 
risk)
Atrial fibrillation: 
1.0; 0.02 – 8.92
B
Inman1994 [23] UK Fluconazole All 1988–1989 15,015 patients Frequencies Different 
categories 
reported
A
National ADR 
databases
Polimeni 2006 [49] Sicilian Antibacterials All 1998–2002 1585 cases ADRs Different 
categories 
reported
A
Sachs 2006 [24] DE Fluoroquinolones Anaphylaxis 1993–2004 204 cases PRR > 2 Moxifloxacin: 2.1;
Ofloxacin: 2.3
Ciprofloxacin: 2.3
Levofloxacin: 2.0
B
Fleisch 2000 [25] CH Levofloxacin Tendinopathy 1986–1999 19 cases/460 
non-cases
Reporting rate Different 
categories 
reported
B
Leone 2003 [26] IT Fluroquinolones Not specified 1999–2001 432 cases/
10,011 non cases
Reporting rate Different 
categories 
reported
A
Pierfitte 2000 [27] FR Sparfloxacin Phototoxicity 1994–1996 371 cases RtR/1000 patients 0.4 B
Frothingham 2005 [28] US Gatifloxacin Glucose 
homeostatis 
abnormalities
1997–2003 453 cases/
1427 non cases
Reporting rate/107 
prescriptions
477 A
Hedenmalm 1996 [29] SE Fluorquinolones Sensory 
disturbances
1965–1993 37 cases ADRs Different 
categories 
reported
ABMC Clinical Pharmacology 2009, 9:4 http://www.biomedcentral.com/1472-6904/9/4
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92]. The tables show that the studies primarily dealt with
analyses of ADRs of the type A and B, and to a lesser extent
C and D. The evidence level of ADRs varied widely; some
of the ADRs were documented in both the analytical and
observational studies, others in only one of the designs.
Data sources
Case-control studies were carried out on data from various
national registers and/or data from spontaneous ADR
databases, physicians' databases such as the General Prac-
titioners' database in the UK and Health Insurance Data-
bases [15,16,37,38,72,73]. The studies were reported in
the literature from the mid-1980s to the end of the 1990s.
Cohort studies analysed ADR data collected from the mid-
1980s to the end of the 1990s. The cohort studies varied
in size from less than 20,000 patients to between 20,000–
50,000 and more than 100,000 patients [17,19,21,40,41].
The PEM studies were conducted in the UK at the Drug
Safety Unit in Southampton, and were based on data col-
lected from the mid-1980s to the end of the 1990s
[22,23,58-66,86-89]. Studies analysing spontaneously
reported ADRs were conducted on large spontaneous
reporting databases such as the French, American, British
and the Uppsala Monitoring Centre WHO database [44-
48,51,55-57,62,74-76,79,82,83,85].
Design and historical perspective
The antibiotic studies were published from 1990 and
onwards, most of them from 1995. Cohort studies were
published during 1990–1994, while the PEM studies,
spontaneous reporting, case reports/case series primarily
were published after 1995. The majority of the NSAID
studies were published after year 2000. The SSRI studies
were published from 1990 to present, most of them from
1995 to 2005. Table 6 shows the distribution of the ana-
lysed studies by type of approach, therapeutic case, and
time of publication. For all therapeutic cases, data were
collected and the studies published a long time after the
drugs were first marketed. Despite the decades of differ-
ence in market launches for the therapeutic cases, the
studies are mainly published from the end of the 1990s
and on. Data were collected earlier.
Explored and detected ADRs
Antibiotics
ADRs from newer types of antibiotics, such as fluoroqui-
nolones, have been reported much more frequently in the
literature than ADRs from the older antibiotics, such as
penicillins and macrolides [15-17,19,20,22-
24,26,29,33,34,36]. The studies explore a possible risk
between the use of antibiotics and the risk of liver, cardi-
ovascular, CNS and dermatological ADRs [18-
20,22,24,27,29,30,32,33,36]. Three cohort studies docu-
mented a correlation between cholestatic hepatitis and
the use of flucloxacillin [18-20]. Increased risk of palpita-
tion from the use of norfloxacin compared to cipro-
floxacin/ofloxacin was demonstrated [22]. Cohort studies
further demonstrated a risk of pemphigus related to peni-
cillins, liver injury related to flucloxacillin and erythromy-
cin [18-21]. CNS and dermatological ADRs from
treatment with antibiotics have been reported rarely and
on the case report level [30,32,33]. New information
about ADRs was only produced by case reports: acute psy-
chotic stress and glossitis/black tongue [34,35].
Case series
Abouesh 2002 [30] - Fluorquinolones
Macrolides
Mania - 102 cases Case review Case review B
Smith 2005 [31] - Doxycycline
Minocycline
ADRs 1966–2003 130 cases Incidences Doxycycline: 
0–61%
Minocycline: 
11.7 – 83.3%
A
Case reports
Hällgren 2003 [32] - Ciprofloxacin Steven-Johnson 
syndrome
1988–2000 8 cases IC pr. 100,000 
patients
0.045 B
Warner 2000 [33] - Clarithromycin Acute Psychotic 
Stress
- 1 case Causality 
assessment
Possible A
ADRAC 1992 [34] - Flucloxacillin Cholestatic 
hepatitis
- 1 case Case review Case review B
Greco 1997 [35] - Clarithromycin Glossitis, 
stomatitis, black 
tongue
- 1 case Case review Case review B
Björnsson 1996 [36] - Doxycycline Liver reactions 1966–1995 23 cases Causality 
assessment
Likely (n = 3)
Possible (n = 8)
B
Table 3: Characteristics of studies of the occurrence of ADRs related to antibiotics use (Continued)BMC Clinical Pharmacology 2009, 9:4 http://www.biomedcentral.com/1472-6904/9/4
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Table 4: Characteristics of studies of the occurrence of ADRs related to NSAID use
Reference Setting Medicines ADRs Sampling 
period
Sample size Outcome 
measures
Results
(95%CI)
Type of 
ADRs
Case control
studies
Hernandez-Diaz 2001[37] UK NSAIDs Gastrointestinal 
events
1993–1998 2,105 cases/
11,500 controls
OR 1.8; 1.3 – 2.4. A
Mockenhaupt 2003 [38] DE/US NSAIDs Steven-Johnson 
syndrome
1989–1995 245 cases/
1147 controls
PRR 34, 95; 11–105 B
Lacroix 2004 [39] FR NSAIDs Liver injury 1998–2000 88 cases/
178 controls
OR Women:
6.49; 1.67–25.16
Men: 1.06; 0.36–3.12
B
Cohort studies
Lipworth 2004 [40] DK Ibuprofen Mortality 1989–1995 113,538
patients
SMR 
(standard mortality 
rate)
1.21; 1.19–1.24 A/B
Ashworth 2004 [41] CA Diclofenac
Naproxen
Arthrotec
Mortality 1991–1994 18,424 patients OR Arthrotec: 1.4; 0.9–2.1.
Diclofenac: 2.0; 1.3–3.1.
Naproxen: 3.0; 1.9–4.6
A/B
Morant 2004 [42] UK NSAIDs Gastrointestinal 
haemorrhage
1987–2001 628000 patient 
year
PRR 0.84; 0.60 – 1.17 A
Martin 2000 [43] UK Meloxicam Gastrointestinal 
events
1996–1997 19,087 patients Events/
1000 patient-
months of 
exposure
Dyspepsia: 28.3
Gastrointestinal 
haemorrhage: 0.4
A + B
National ADR databases
Lugardon 2004 [44] FR COX-2 
inhibitors
Oeso-gastro-
duodenal events:
2000–2002 505 cases/
2,525 non-cases
OR 14.9; 9.3–23.7 A
Durrieu 2005 [45] FR COX-2 
inhibitors
Arterial 
hypertension
2000–2003 34 cases OR 3.3; 1.6–6.9. A
Clinard 2004 [46] FR NSAIDs Excess risk of 
adverse drug 
reactions
1995–1999 3983 cases/
54,583 non- cases
OR Different categories 
reported
B
Brinker 2004 [47] US COX-2 
inhibitors
Hypertension < 2002 34 cases Reporting rate/
106person years
Rofecoxib: 5.0
Celecoxib: 1.3
A
La Grenade 2005 [48] US COX-2 
inhibitors
Meloxicam
Steven-Johnson 
syndrome
Toxic Epidermal 
Necrolysis
< 2004 123 cases Reporting rate/
106person years
Valdecoxib: 49
Celecoxib: 6
Rofecoxib: 3
B
Polimeni 2006 [49] Sicilian NSAIDs All 1998–2002 1585 cases PRR Hepatitis: 14.20
Vasculitis: 7.72
Hypertension: 15.40
B
Conforti 2001 [50] IT NSAIDs Gastrointestinal 
events
1996–1999 705 cases/
10,608 non cases
% ADRs Nimesulid: 10.4
Diclofenac: 21.2
Ketoprofen: 1.7
Piroxicam: 18.6
A
Ahmad 2002 [51] US COX-2 
inhibitors
Renal failure 1969–2000 Celecoxib: 122 
cases
Rofecoxib: 142 
cases
Case review Case review A
Puijenbroek 2000 [52] NL NSAIDs
Diuretics
Drug interactions 1990–1999 305 cases/
9517 non cases
OR OR: 2.0, 1.1–3.7 D
Lapeyre-Mestre 2004 [53] FR/ES NSAIDs Hepatic events 1982–2001 29,486 cases OR Different OR calculated 
for NSAIDs.
BBMC Clinical Pharmacology 2009, 9:4 http://www.biomedcentral.com/1472-6904/9/4
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Leone 1999 [54] IT Nimesulide Renal impairment 1988–1997 11cases/
7438 non cases
Causality 
assessment
Possible (n = 6)
Probable (n = 4)
Certain (n = 1)
A
Brown 1998 [55] UK Tiaprofenic 
acid
Cystitis 1981–1996 221 cases/
1327 non cases
ADRs/105 
prescriptions
1991: 4.2
1992: 5.9
1993: 4.2
1994: 34.4
1995: 18.5
1996: 6.5
B
Verrico 2003 [56]U S C O X 2 -
inhibitors
Not specified 1999–2002 24 cases Causality 
assessment
Possible (n = 29)
Probable (n = 16)
A
Kahn 1997 [57] US NSAIDs Necrotizing soft 
tissue infections
1969–1995 33 cases Case review N = 26 C
PEM
Layton 2004a [58] UK Celecoxib Not specified 2000 17,458 patients IDs (event 
incidence 
densitites)
Dyspepsia = 25.4
Abdominal pain = 10.6
A + B
Layton 2003b [59] UK Celecoxib
Meloxicam
Not specified 1996–1997 34,355 patients PRR Different categories 
reported
A
Layton 2003c [60] UK Rofecoxib Not specified 2000 15,268 patients Event rate pr. 1000 
patient months 
exposure
76 upper GI bleedings and 
101 thromboembolic 
events
A + B
Layton 2004d [61] UK Rofecoxib Exacerbation of 
colitis
1999 15,268 patients IRR 5.8; 2.7–11.3 A
Kasliwal 2005 [62] UK COX-2 
inhibitors
Gastrointestinal +
thromboembolic 
events
1999–2000 32,726 patients PRR GI: 1.21; 1.09 – 1.36.
Thromboembolic: 1.04; 
0.50 – 2.17.
A + B
Layton 2003e [63] UK Rofecoxib
Meloxicam
Thromboembolic 
events
1996–1997 34,355 patients PRR 1.68; 1.15 – 2.46. A
Layton 2003f [64] UK Rofecoxib
Meloxicam
Upper GI events 1996–1997 34,355 patients IR 0.71; 0.65 – 0.79. A
Layton 2006g [65] UK COX-2 
inhibitors
Serious skin 
reactions
1999–2000/ 52,644 patients IR/1000 patient-
months
IR: 0.019 B
Layton 2003h [66] UK Celecoxib
Meloxicam
Gastrointestinal 
events
1996–1997 36,545 patients PRR 0.77; 0.69 – 0.85. A
Case series
Onder 2004 [67] - NSAIDs Psychiatric ADRs 1965–2003 27 reports with 
data on 453 cases
Risk factors Age, psychiatric 
disorders, parturients
B
Fraunfelder 2006 [68] - NSAIDs Ocular ADRs - 569 cases Reported ADRs Blurred vision, 
conjunctivitis, visual 
hallucinations
B
Zimer 2007 [69] DE Valdecoxib Cutaneous adverse 
reactions
2002–2005 5 cases Case review Erythematous, facial 
edema, dyspnea
B
Case reports
Hunter 1999 [70] - Bromfenac Hepatic Failure - 1 case Causality 
assessment
Related B
ADRAC 1998 [71]- D i c l o f e n a c
Indomethacin
Mefenamic 
acid
Closure of fetal 
ductus arterious
- 3 cases Case review Case review C
Table 4: Characteristics of studies of the occurrence of ADRs related to NSAID use (Continued)BMC Clinical Pharmacology 2009, 9:4 http://www.biomedcentral.com/1472-6904/9/4
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Table 5: Studies of the occurrence of ADRs related to SSRI use
Reference Setting Medicines ADRs Sampling 
period
Sample size Outcome 
measures
Results
(95% CI)
Type of 
ADRs
Case-control 
studies
Schillevoort 2002 [72] NL SSRIs Extrapyramidal
Syndromes (EPS)
1985–1999 41cases/1,264 
controls
OR 2.2; 1.2–3.9 A
Movig 2002 [73] NL SSRIs Hyponatraemia 1990–1998 203 cases/608 
controls
OR 3.96; 1.33 – 11.83 A
Cohort study
Bell 2006 [74] US Fluoxetine Testosterone 
levels
- 14 patients Testosterone 
level
No changes B
National ADR 
databases
Trenque 2002 [75] FR SSRIs Withdrawal 
syndrome
< 2000 60 cases/166,327 
non cases
OR 5.05, 3.81–6.68. A
Gony 2003 76] FR SSRIs Extrapyramidal
Symptoms
1995–2000 9 cases OR 2.18; 0.47–11.35 A
Hedenmalm 2006 [77] SE SSRIs Alopecia < 2004 27 cases IC Sertraline = 1.63, 
0.85–2.41
Citalopram = 1.22, 
0.97–1.47
B
Goldstein 1997 [78] - Fluoxetine First-trimester 
exposure on 
newborns
< 1996 796 cases Rate % 5.0 C
Spigset 2003 [79] SE Nefazodone Hepatic injury < 2002 27,542 cases/
2830764 non 
cases
IC 0.42, 0.12–0.72 B
Khan 2003 [80] US SSRIs Suicide 1985–2000 77 cases/48,277
non cases
Suicide rate 0.59, 0.31 – 0.87 A
Egberts 1997 [81] NL SSRIs Non-puerperal 
lactation
1986–1996 38cases/14,439 
non cases
OR 2.7; 6.4–25.4 A
Kvande 2001 [82] NO SSRIs Pancreatitis < 2000 160 cases No. of cases 160 cases B
Stahl 1997 [83] SE SSRIs Withdrawal 
reactions
< 1995 49, 393 cases Number of 
reports/106/
DDD
Paroxetine = 1.9
Sertraline = 2.1
Fluoxetine = 0.48
A
Spigset 1999 [84] SE SSRIs Not specified 1965–1997 1202 cases ADRs Different categories 
reported
A + B
Sanz 2005 [85] SE SSRIs Neonatal 
withdrawal 
syndrome
1968–2002 102 cases IC Paroxetine = 4.07
Sertraline = 1.20
Citalopram = 1.92
Fluoxetin = 1.07
C
PEM
Price 1996 [86] UK SSRIs Withdrawal 
reactions
1987–1992 50,150 patients Reports/
1000 
prescriptions
Paroxetine = 0.3
Sertraline = 0.03
Fluvoxamine = 0.03
Fluoxetine = 0.002
A
Layton 2001 [87] UK SSRIs Abnormal bleeding 1986–1998 135,754 patients PRR Day 1–30 = 1.38
Month 2–6 = 1.17
ABMC Clinical Pharmacology 2009, 9:4 http://www.biomedcentral.com/1472-6904/9/4
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NSAIDs
Studies explored the risk of gastrointestinal [37-44,50]
and dermatological ADRs as well as the development of
liver and kidney toxicity which are well known ADRs asso-
ciated with NSAIDs and their pharmacological character-
istics[38,39,48,51,53,54,57,65,69,70]. The studies were
generated after the launch of COX-2 inhibitors in the mid-
1990s. A case-control study documented increased risk of
developing dermatological ADRs of the type Steven-John-
son Syndrome and toxic epidermal necrolysis as did spon-
taneously reported ADRs [38,48]. A case-control study
documented hepatic injury related to the use of NSAIDs,
as did spontaneously reported ADRs, while renal injury
and hypertension was documented in spontaneous
reports and thromboembolic events in a PEM study
[39,45,47,51,53,54,63,70]. With the exception of case
reports, the approaches used did not produce information
about ADRs that had not been reported previously.
SSRIs
Studies explored the risk of extrapyramidal symptoms,
withdrawal syndromes and serotonin syndrome with the
use of SSRIs, other ADRs investigated were: changes in tes-
tosterone and natrium level, alopecia, liver injury and
bleeding. ADRs reported only via spontaneous reports are
first-trimester exposure on newborns and neonatal with-
drawal syndrome, hepatic injury and pancreatitis, suicide,
non-puerperal lactation and serotonin syndrome [72-
81,79,83,85,86,90-92]. With the exception of case
reports, the approaches used did not detect new ADR sig-
nals that had not been reported previously [90-92].
Information about ADRs reported across approaches
Analytical
The approaches produced information about ADR risks
compared to placebo or similar drugs as either odds ratios
(OR), proportional reporting ratio (PRR) estimates, inci-
dences (IC) and frequencies of ADRs. These parameters
are built into the design and based on previous informa-
tion or hypothesis. The studies were conducted on various
patient populations, various medicines within the indi-
vidual sub-groups, and different types of ADRs, different
outcome measures, data sources and time periods. The
purpose of the approaches made it possible to adjust the
ADR estimate for known confounders and risk factors.
Observational
The approaches produced information about ADRs as
estimates (OR, PRR, IC) or as single observations com-
pared to placebo/similar medicines. Case reporting was
the only approach that contributed new information
about new ADRs in all three therapeutic cases.
Discussion
This review has several main findings:
First, analytical approaches ranging higher in the evidence
hierarchy provided information about risks of already
known or expected ADRs, while information about new
and unknown ADRs was detected by case reports only,
which range at the lowest level in the evidence hierarchy.
Second, the studies primarily dealt with analyses of ADRs
of type A and B, and only a few studies analysed type C
and D. Third, similar approaches, both analytical and
observational, were applied to all therapeutic cases.
Fourth, the ADR cases provided similar results with regard
to detecting new ADRs despite their connection to differ-
ent time periods and organs attacked.
Methodological quality and capability of approaches
There is a general lack of standards in the field of ADRs,
particularly because many ADRs are not detected until
after marketing and the studies are based on selected
patient groups, which makes it difficult to generalise the
results to other patient groups. As previously argued in the
literature, testing specific hypotheses in the analytical
Edwards 1994 [88] UK Fluvoxamine All 1987–1988 10,401 patients Incidences A
MacKay 1997 [89] UK SSRIs All 1988–1991 56,145 patients Nausea, vomiting, 
withdrawal 
symptoms
Case series
de Abajo 2006 [90]- S S R I s
Venlafaxine
Bleeding Disorders 1988–2003 1,651 cases/
10,000 controls
PRR 3.0, 2.1–4.4 A
Gram 1999 [91] DK SSRIs Bleeding
Thrombocytopenia
- 8 cases - Case review A + B
Case report
Demers 2001 [92] - Fluvoxamine Serotonin 
syndrome
- 1 case - Case review A
Table 5: Studies of the occurrence of ADRs related to SSRI use (Continued)BMC Clinical Pharmacology 2009, 9:4 http://www.biomedcentral.com/1472-6904/9/4
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approaches makes it difficult to capture information
about new and unknown ADRs [13]. Despite the fact that
these types of studies rank high in the evidence hierarchy,
the weaker design of the observational studies makes
them more suitable for discovering previously undetected
ADRs. Healthcare professionals have conventionally con-
sidered cohort and case-control studies to be well suited
for post-marketing surveillance of ADRs, despite their lack
of randomisation and lower position in the evidence hier-
archy, level 4 and 5 respectively [14]. These studies prima-
rily detected/analysed ADRs of type A and B and less
frequently type C and D [14]. Thus, the approaches are
not designed and therefore are not suitable for predicting
new information about other ADRs that have not previ-
ously been detected or ADRs of the type C or D [14]. Case
reports have provided data about patients, suspected
ADRs, medicines involved and so on, but this information
is often anecdotal in nature and collected retrospectively.
However, it is interesting that despite their low rank in the
evidence hierarchy, these reports provide new informa-
tion about rare and previous undetected ADRs. Case
reports may serve as whistleblowers, thereby initiating
larger systematic analyses of patient populations or regis-
tering data to quantify the risk. A large majority of sponta-
neously reported ADRs are stored in databases hosted by
regulatory agencies. Information about these observations
is typically only released to the public in the form of press
releases, insertions in product information or messages in
national bulletins. If all these signals were published in
the scientific literature or made public on the web pages
of regulatory agencies, the number of spontaneous
reports/case series would probably have been larger and
added to the relative dominance of this design [93,94].
The results confirm that spontaneous post-marketing
Table 6: Number of studies categorised by number, design and time of publication
Year of 
publication
< 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005-
Study design
Antibiotics
Case control 
studies
11
Cohort studies 1 3 1
National ADR 
databases
12 1 2
PEM* 1 1
Case series 11
C a s e  r e p o r t s 1 1 111
NSAIDs
Case control 
studies
11 11
Cohort studies 13
National ADR 
databases
11111114 3
PEM* 52 2
Case series 12
Case reports 1 1
SSRIs
Case control 
studies
2
Cohort studies 1
National ADR 
databases
311 1 3 2
PEM* 1 1 1 1
Case series 11
Case reports 1
*Prescription Event Monitoring StudiesBMC Clinical Pharmacology 2009, 9:4 http://www.biomedcentral.com/1472-6904/9/4
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reporting of ADRs is of great importance and that regula-
tory agencies must continue to encourage spontaneous
reporting of ADRs [93,94].
Alternative signal detection approaches
New ADR signals are often documented by only a small
number of case reports, and systematic inclusion of data
mining procedures in assessment of new ADR signals
would probably contribute to earlier detection and quan-
tification of serious ADR signals [95,96]. However, data
mining was not applied in the three therapeutic cases
studied here. Examples of data mining are cumulative
techniques, time scans and Poisson methods, propor-
tional reporting ratios (PRRs) and Bayesian data mining
[97]. These methods assess how much the observed
reporting frequency of a given drug-event combination
deviates from that expected, given statistical independ-
ence between drug and event. Methodological and practi-
cal experiences with data mining in signal detection are
limited [97,98].
Strengths and limitations of the study
The objective of this review was to analyse which informa-
tion signal detection approaches have produced about
new ADRs in selected and published therapeutic cases,
rather than to perform a systematic review of the entire
body of ADR literature covering all therapeutic groups.
The choice of widely different therapeutic cases and the
similar results obtained across therapeutic cases make us
believe that the results qualitatively reflect the general,
published experience on ADRs based on signal detection
approaches. Findings across therapeutic cases were similar
with respect to methodological approaches and time of
publication, despite the fact that ADRs differed in nature
and affected different organs. Although antibiotics have
been marketed since the 1940s, it was not possible to
search for literature before the mid-1960s due to the lim-
itations of current databases. Lack of consistency in
reporting ADRs, different methodologies used in the stud-
ies and their impact on the results are difficult to evaluate
in this review.
Conclusion
Although the medicines were launched in different dec-
ades, approaches to the ADR studies were similar for all
three therapeutic cases: antibiotics, NSAIDs and SSRIs.
Descriptive as well as analytical designs were applied.
Despite the fact that the analytical studies rank higher in
the evidence hierarchy, only the descriptive case reports/
spontaneous reports provided information about new
and previously undetected ADRs. This review underscores
the importance of systems for spontaneous reporting of
ADRs. Therefore, spontaneous reporting should be
encouraged further and the information in ADR databases
should continuously be subjected to systematic analysis.
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